Recent Update in Pharmacological Agents for Optic Pathway Glioma

Area of Science:

• Neuro-oncology
• Ophthalmology
• Pediatric oncology

Background:

• Optic pathway gliomas (OPGs) are low-grade tumors impacting the optic nerve, chiasm, and tracts.
• These tumors can be sporadic or linked to neurofibromatosis type 1 (NF1).
• Tumor location often prevents complete surgical removal or effective radiation therapy.

Purpose of the Study:

• To review the current treatment landscape for OPGs.
• To highlight the limitations of existing therapies and the need for standardized outcome measures.
• To explore emerging molecularly targeted therapies for OPGs.

Main Methods:

• Literature review of OPG treatments.
• Analysis of chemotherapy outcomes.
• Evaluation of novel targeted therapy approaches.

Main Results:

• Chemotherapy is the primary treatment for progressive OPGs, but results are variable.
• Standardized outcome measurements for OPGs are currently lacking.
• Targeted therapies, including anti-VEGF, MAPK, and mTOR inhibitors, present a promising new treatment avenue.

Conclusions:

• Effective management of OPGs remains challenging due to tumor location and treatment variability.
• There is a critical need for standardized outcome assessments in OPG clinical trials.
• Molecularly targeted therapies offer a potentially more effective treatment modality for OPGs, warranting further investigation.